FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313595422> ?p ?o ?g. }

• W4313595422 abstract "The Fc region of monoclonal antibodies (mAbs) interacts with the CD16a receptor on natural killer (NK) cells with low affinity and low selectivity. This low affinity/selectivity interaction results in not only suboptimal anticancer activity but also induction of adverse effects. CD16a on NK cells binds to the antibody-coated cells, leading to antibody-dependent cell-mediated cytotoxicity (ADCC). Recent clinical data have shown that the increased binding affinity between mAb Fc region and CD16a receptor is responsible for significantly improved therapeutic outcomes. Therefore, the objective of this study was to develop a bispecific killer cell engager (BiKE) with high affinity and specificity/selectivity toward CD16a receptor for NK cell-based cancer immunotherapy.To engineer BiKE, a llama was immunized, then high binding anti-CD16a and anti-HER2 VHH clones were isolated using phage display. ELISA, flow cytometry, and biolayer interferometry (BLI) data showed that the isolated anti-CD16a VHH has high affinity (sub-nanomolar) toward CD16a antigen without cross-reactivity with CD16b-NA1 on neutrophils or CD32b on B cells. Similarly, the data showed that the isolated anti-HER2 VHH has high affinity/specificity toward HER2 antigen. Using a semi-flexible linker, anti-HER2 VHH was recombinantly fused with anti-CD16a VHH to create BiKE:HER2/CD16a. Then, the ability of BiKE:HER2/CD16a to activate NK cells to release cytokines and kill HER2+ cancer cells was measured. As effector cells, both high-affinity haNK92 (CD16+, V176) and low-affinity laNK92 (CD16+, F176) cells were used.The data showed that the engineered BiKE:HER2/CD16a activates haNK92 and laNK92 cells to release cytokines much greater than best-in-class mAbs in the clinic. The cytotoxicity data also showed that the developed BiKE induces higher ADCC to both ovarian and breast cancer cells in comparison to Trazimera™ (trastuzumab). According to the BLI data, BiKE:HER2/CD16 recognizes a different epitope on CD16a antigen than IgG-based mAbs; thus, it provides the opportunity for not only monotherapy but also combination therapy with other antibody drugs such as checkpoint inhibitors and antibody-drug conjugates. Taken together, the data demonstrate the creation of a novel BiKE with high affinity and specificity toward CD16a on NK cells with the potential to elicit a superior therapeutic response in patients with HER2+ cancer than existing anti-HER2 mAbs." @default.
• W4313595422 created "2023-01-06" @default.
• W4313595422 creator A5015915988 @default.
• W4313595422 creator A5035426386 @default.
• W4313595422 creator A5052447531 @default.
• W4313595422 creator A5076447881 @default.
• W4313595422 creator A5076933986 @default.
• W4313595422 creator A5086485895 @default.
• W4313595422 date "2023-01-06" @default.
• W4313595422 modified "2023-10-06" @default.
• W4313595422 title "Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy" @default.
• W4313595422 cites W1602010694 @default.
• W4313595422 cites W1972475421 @default.
• W4313595422 cites W1991656907 @default.
• W4313595422 cites W1993488923 @default.
• W4313595422 cites W2000061036 @default.
• W4313595422 cites W2051944033 @default.
• W4313595422 cites W2068071851 @default.
• W4313595422 cites W2075901113 @default.
• W4313595422 cites W2089570814 @default.
• W4313595422 cites W2093322080 @default.
• W4313595422 cites W2109502548 @default.
• W4313595422 cites W2109638333 @default.
• W4313595422 cites W2127214162 @default.
• W4313595422 cites W2169782526 @default.
• W4313595422 cites W2221432805 @default.
• W4313595422 cites W2325393979 @default.
• W4313595422 cites W2556149828 @default.
• W4313595422 cites W2762643625 @default.
• W4313595422 cites W2772621511 @default.
• W4313595422 cites W2788848550 @default.
• W4313595422 cites W2802502457 @default.
• W4313595422 cites W2811247652 @default.
• W4313595422 cites W2898500666 @default.
• W4313595422 cites W2911699089 @default.
• W4313595422 cites W2925727197 @default.
• W4313595422 cites W2949916509 @default.
• W4313595422 cites W2976861282 @default.
• W4313595422 cites W3000345307 @default.
• W4313595422 cites W3011458562 @default.
• W4313595422 cites W3033329685 @default.
• W4313595422 cites W3099607932 @default.
• W4313595422 cites W3123743675 @default.
• W4313595422 cites W3134466246 @default.
• W4313595422 cites W3161220247 @default.
• W4313595422 cites W3195161684 @default.
• W4313595422 cites W4206980672 @default.
• W4313595422 cites W4284971931 @default.
• W4313595422 doi "https://doi.org/10.3389/fimmu.2022.1039969" @default.
• W4313595422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36685519" @default.
• W4313595422 hasPublicationYear "2023" @default.
• W4313595422 type Work @default.
• W4313595422 citedByCount "3" @default.
• W4313595422 countsByYear W43135954222023 @default.
• W4313595422 crossrefType "journal-article" @default.
• W4313595422 hasAuthorship W4313595422A5015915988 @default.
• W4313595422 hasAuthorship W4313595422A5035426386 @default.
• W4313595422 hasAuthorship W4313595422A5052447531 @default.
• W4313595422 hasAuthorship W4313595422A5076447881 @default.
• W4313595422 hasAuthorship W4313595422A5076933986 @default.
• W4313595422 hasAuthorship W4313595422A5086485895 @default.
• W4313595422 hasBestOaLocation W43135954221 @default.
• W4313595422 hasConcept C114684123 @default.
• W4313595422 hasConcept C147483822 @default.
• W4313595422 hasConcept C153911025 @default.
• W4313595422 hasConcept C159654299 @default.
• W4313595422 hasConcept C167672396 @default.
• W4313595422 hasConcept C185592680 @default.
• W4313595422 hasConcept C203014093 @default.
• W4313595422 hasConcept C2777701055 @default.
• W4313595422 hasConcept C2780674031 @default.
• W4313595422 hasConcept C2781462264 @default.
• W4313595422 hasConcept C40677261 @default.
• W4313595422 hasConcept C502942594 @default.
• W4313595422 hasConcept C542903549 @default.
• W4313595422 hasConcept C553184892 @default.
• W4313595422 hasConcept C86803240 @default.
• W4313595422 hasConcept C8891405 @default.
• W4313595422 hasConceptScore W4313595422C114684123 @default.
• W4313595422 hasConceptScore W4313595422C147483822 @default.
• W4313595422 hasConceptScore W4313595422C153911025 @default.
• W4313595422 hasConceptScore W4313595422C159654299 @default.
• W4313595422 hasConceptScore W4313595422C167672396 @default.
• W4313595422 hasConceptScore W4313595422C185592680 @default.
• W4313595422 hasConceptScore W4313595422C203014093 @default.
• W4313595422 hasConceptScore W4313595422C2777701055 @default.
• W4313595422 hasConceptScore W4313595422C2780674031 @default.
• W4313595422 hasConceptScore W4313595422C2781462264 @default.
• W4313595422 hasConceptScore W4313595422C40677261 @default.
• W4313595422 hasConceptScore W4313595422C502942594 @default.
• W4313595422 hasConceptScore W4313595422C542903549 @default.
• W4313595422 hasConceptScore W4313595422C553184892 @default.
• W4313595422 hasConceptScore W4313595422C86803240 @default.
• W4313595422 hasConceptScore W4313595422C8891405 @default.
• W4313595422 hasFunder F4320306784 @default.
• W4313595422 hasFunder F4320332161 @default.
• W4313595422 hasFunder F4320337338 @default.
• W4313595422 hasLocation W43135954221 @default.
• W4313595422 hasLocation W43135954222 @default.
• W4313595422 hasLocation W43135954223 @default.

• next